Research programme: protein-protein interaction inhibitors - Debiopharm
Alternative Names: Debio 0928Latest Information Update: 16 Jul 2016
At a glance
- Originator H. Lee Moffitt Cancer Center and Research Institute
- Developer Debiopharm Group
- Class Small molecules
- Mechanism of Action Cell cycle inhibitors; Protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in Switzerland
- 18 Jun 2009 Preclinical trials in Solid tumours in Switzerland (unspecified route)